In future, more comprehensive research needs to be done to unravel the protein and gene molecules along the complex EGFR signalling pathway in ovarian cancer to identify biomarkers that can accurately gauge the sensitivity of EGFR-targeted therapeutic agents. The gene discussed is EGFR; the disease is ovarian carcinoma.